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Abstract
Stem cells are unspecialized cells capable of renewing themselves and giving rise 
to differentiated and specialized cell subtypes. There are two general categories of 
stem cells, i.e., pluripotent stem cells capable of differentiation into any cell type in 
the human body and multipotent adult stem cells maintaining tissue homeostasis 
in postnatal life. Investigations in both these categories of stem cells have expanded 
our knowledge on human organogenesis and tissue regeneration and have suggested 
potential therapeutic functions of stem cells in regenerative medicine. The advent 
of induced pluripotent stem cell (iPSC) technology a decade ago further revolu-
tionized stem cell biology and has given rise to the translation of stem cell-based 
therapies. This chapter will summarize some of the exciting progress and challenges 
in the applications of iPSC-derived stem cells and adult stem cells and the potential 
of translational and clinical research of these stem cells in regenerative medicine.
Keywords: stem cells, regenerative therapy, clinical studies, iPSCs, cord blood,  
adult stem cells
1. Introduction
Stem cells are a unique subset of cells that possess the biological properties of 
self-renewal and differentiation. The term “Stammzelle” (German for stem cell) 
was first used by a German biologist Ernst Haeckel in 1868 regarding unicellular 
organisms as the phylogenetic ancestors of multicellular organisms [1]. In 1877, 
Haeckel further applied the notion of stem cells to describe the fertilized egg cell as 
the cell of origin for all the cells in an organism [2].
Indeed, there are stem cells of different potency that not only form the foun-
dation of any organisms but also throughout the life of the organism maintain 
tissue homeostasis. Following egg fertilization with a sperm, a zygote is generated 
(Figure 1A). This single-cell zygote and the cells that immediately arise in the first 
few divisions are totipotent stem cells, as they are capable of becoming a whole 
embryo including the extra-embryonic tissue, i.e., placenta. After about 5 days of 
human embryonic development, the zygote develops into a blastocyst. The preim-
plantation blastocyst consists of a mostly hollow ball of cells, with the outer cell 
layer as trophoblast that develops into the placenta and the inner cell mass (ICM) 
that is pluripotent and gives rise to all cell types in the body. These pluripotent stem 
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cells (PSCs) in the ICM are the source for embryonic stem (ES) cells [3]. Apart 
from PSCs, there are tissue-specific stem cells residing in several organs such as the 
skin, gut, blood, and brain, also referred to as “adult” or “somatic” stem cells with 
self-renewal and multipotent differentiation capacity that are responsible for most 
regenerative activities throughout the life of the organism.
2. Pluripotent stem cells (PSCs)
2.1 ES cells
The culture of ES cells from mouse blastocysts was first reported by Evans et al. 
in 1981 and herein opened a new era of research in gene targeting to model human 
Figure 1. 
Derivation of pluripotent stem cells (PSCs) including embryonic stem cells (ESCs) from fertilization of oocytes 
and sperm (A), nuclear transfer ESCs (NT-ESCs) from somatic cell nuclear transfer (SCNT) of somatic cell 
nuclei into denucleated oocytes (B), and induced pluripotent stem cells from forced expression of Yamanaka 
transcription factors in somatic cells (C). All the three types of PSCs can be propagated extensively in vitro and 
undergo directed differentiation into any cell type of the body, which can be utilized in disease modeling and 
drug screening and developed as cell-based therapies. As generation of ESCs involve disruption of the embryos, 
they can only be used as an allogenic source, while NT-ESCs and iPSCs can be developed in both allogenic and 
autologous settings.
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diseases [3]. Based on this technology, Martin Evans, Mario Capecchi, and Oliver 
Smithies shared the 2007 Nobel Prize for their discoveries of principles for intro-
ducing specific gene modifications in mice by the use of ES cells. In 1998, Thomson 
and collaborators reported the derivation of ES cell lines from human blastocysts 
produced by in vitro fertilization (IVF) [4]. As these human ES cells are immortal 
and can give rise to all cell types in the body, they are invaluable tools to dissect the 
molecular and genetic events in human development and also allow drug testing in 
a wide range of diseases (Figure 1). Moreover, human ES cells provide an unlim-
ited source to derive cells and tissues that could be used as cell-based therapies to 
treat degenerative diseases such as heart disease and type 1 diabetes (Figure 1). 
Indeed, detailed differentiation protocols have been developed to derive specific 
mature cells from human ES cells, for example, dopaminergic neurons, cardiomy-
ocytes, β cells, and keratinocytes as therapies for Parkinson’s disease, myocardial 
infarction, type I diabetes, and skin disease, respectively. However, as the deriva-
tion of ES cells involves destruction of human embryos, even though the embryos 
were produced by IVF and would otherwise be discarded, it nevertheless has 
raised ethical concerns and elicited controversial debates on the use of human ES 
cells [5]. Another hurdle for the therapeutic use of ES-derived cells is that they can 
only be used as allogeneic cells; thus they are subject to immune-based rejection in 
their recipients [6].
2.2 PSCs derived from reprogramming
The 2012 Nobel Prize in Physiology or Medicine was awarded to two scien-
tists, Sir John B. Gurdon and Shinya Yamanaka, PhD, whose stem cell research 
was separated by over four decades but both demonstrated that the developmen-
tal clock of a specialized cell can be turned back to an immature (pluripotent) 
state. In John B. Gurdon’s classic experiment in 1962, he replaced the nucleus 
in an egg cell of a frog with the nucleus from a mature intestinal cell [7]. The 
modified egg cell subsequently developed into a normal tadpole. Using the 
same principle of Gurdon’s work which is known as somatic cell nuclear transfer 
(SCNT), the first mammalian clone “Dolly the Sheep” was born in 1996, fol-
lowing transfer of the nucleus from a mammary gland into an enucleated sheep 
egg [8]. Therefore, factors presented in mature, metaphase II-arrested oocyte 
cytoplasm are capable of reprogramming somatic cell nuclei to an undifferenti-
ated state. This unique ability of oocytes has led to an important application of 
utilizing SCNT in therapeutic cloning to generate ES cells (ESCs) (NT-ESCs) for 
regenerative medicine (Figure 1B).
Forty-four years after Gurdon’s discovery, Shinya Yamanaka took a different 
approach and transduced the differentiated mammalian cells, i.e., fibroblasts with 
a cocktail of reprogramming factors (Oct3/4, Sox2, Klf4, and c-Myc) using retrovi-
ruses (Figure 1C) [9]. About 30 days after transduction, induced pluripotent stem 
cells (iPSCs) with properties similar to ES cells were generated at an efficiency of 
~0.02% [9]. After the initial discovery of Yamanaka’s reprogramming techniques, 
several other reprogramming methods, such as transduction with nonintegrating 
viruses (adenovirus and Sendai virus) or transfection with protein, mRNA, Piggy 
Bac element, minicircle vectors, and episomal plasmids, have been developed to 
produce iPSCs without integration of exogenous genes to the genome of recipient 
cells (reviewed in [10]). iPSCs can also be generated from more easily accessible cell 
sources such as blood [11].
Therefore, the PSCs produced by SCNT (NT-ESCs) and forced expression 
of reprogramming transcription factors (iPSCs) are both alternatives to ESCs 
in regenerative medicine. Epigenetic and transcriptomic comparisons between 
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isogenic iPSCs and NT-ESCs have demonstrated that NT-ESCs more closely resem-
ble bona fide ESCs derived from fertilized embryos [12, 13]. Moreover, a most 
important difference between iPSCs and NT-ESCs is the source of mitochondrial 
DNA (mtDNA). The mtDNA in NT-ESCs is of an oocyte germline origin, while in 
iPSCs is of a parental somatic origin. Due to the random nature of somatic mtDNA 
mutations, the frequency of mtDNA defects in iPSCs has been demonstrated to 
increase with the age of somatic cells [14]. Thus, NT-ESCs, carrying mutation-free 
mtDNA and closely resembling ESCs, represent an invaluable stem cell source 
for regenerative medicine. However, as the derivation of NT-ESCs requires donor 
oocytes, which are more technically challenging than iPSCs and are also subject 
to ethical and/or legal restrictions, the majority of current PSC research has been 
carried out using iPSCs.
2.3 iPSC disease modeling
These groundbreaking discoveries have revolutionized our understanding 
of stem cell development and created novel opportunities for human disease 
modeling and drug screening in “disease-in-a-dish” models (Figure 1) [15]. To 
date, significant progress has been made utilizing human iPSCs to model various 
neurological disorders, inherited heart diseases, and other genetic diseases such 
as Duchene muscular dystrophy and recessive dystrophic epidermolysis bullosa 
(RDEB) [16, 17]. Utilizing amyotrophic lateral sclerosis (ALS), also called Lou 
Gehrig’s disease as an example, ALS is a neurodegenerative disease that primarily 
affects corticospinal “upper” motor neurons (UMNs) and spinal cord “lower” 
motor neurons (LMNs), resulting in progressive muscle weakness [18]. In about 
10% of patients with ALS, the disease runs in the family (familiar ALS) with 
mutations in around 20 genes including SOD1, TARDBP, FIS, and C9orf72 identi-
fied as common causes [18]. The remaining 90% of the patients are classified as 
sporadic ALS, with the causative mutations largely unidentified. As the iPSCs 
generated from ALS patients and differentiated into motor neurons carry the same 
genetic background as the patients, it represents a novel tool for studying disease 
pathology of ALS, particularly the sporadic form, which is not possible in the other 
model systems. A proof-of-principle study on derivation of iPSCs from an ALS 
patient and differentiation into LMNs was reported in 2008 [19]. Subsequently, 
Kiskinis et al. and Chen et al., respectively, established in vitro models of ALS 
by generating iPSC-derived LMNs from patients carrying different SOD1 muta-
tions. Both studies recapitulated the spontaneous and progressive decrease in cell 
viability and ALS-related morphological changes including reduction in soma size 
and altered dendrites, which was linked to neurofilament aggregation [20, 21]. 
Chen et al. further demonstrated the pathological features of mutated SOD1 in 
patient-derived MNs, but not in non-MNs. Only in MNs, mutated SOD1 bound 
to the 3′UTR region of neurofilament (NF)-L mRNA resulted in neurofilament 
aggregation, restoring the expression of NF-L mitigated neurite degeneration of 
the ALS-iPSC-derived MNs. Meanwhile, Wainger et al. generated iPSC-derived 
LMNs from patients carrying SOD1, C9orf72, or FUS mutations [22]. All these 
ALS-iPSC-derived LMNs with distinct genetic mutations have recapitulated 
essential disease features and discovered common molecular pathways driving 
ALS pathogenesis, opening the possibility of new and effective drug screening 
[23]. However, challenges still remain for in vitro modeling for ALS using iPSCs 
[18]. Different protocols have been reported in deriving LMNs from iPSCs; thus, 
criteria need to be established to compare the MNs generated using different 
methods. Moreover, generation of UMNs from PSCs involves a series of steps and 
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is more challenging than that of LMNs [18]. The current protocols for deriving 
UMNs mostly resulted in heterogeneous, neocortical-like neurons that are imma-
ture and “stalled” at a stage resembling mid-embryonic differentiation in vivo 
[24]. Therefore, promoting subtype-specific differentiation and maturation will 
be crucial to an accurate ALS modeling. Indeed, the abilities of iPSC-derived cells 
to exhibit maturation and aging are crucial for accurate in vitro modeling of all the 
adult-onset diseases.
2.4 iPSC-based therapies
The most significant advantage of iPSCs lies in its application in cell-based 
therapies. iPSCs can be developed without destroying human embryos, therefore 
circumventing the ethical obstacles of utilizing and generating human ES cells. 
Being able to differentiate into all cell types in the body similar to ES cells, iPSCs 
theoretically provide an unlimited source of cells for autologous transplantation, 
eliminating the need for immunosuppression. Moreover, scientists have established 
robust directed differentiation protocols with sequential activation and inhibition 
of molecular differentiation pathways to generate a wide range of somatic cells from 
iPSCs, such as β cells and cardiomyocytes (Figure 1).
A challenge for the PSC or iPSC differentiation, as also mentioned above in the 
iPSC-derived MNs, is that the PSC-derived cells tend to be immature. This is indeed 
the major limitation for translating iPSC-derived red blood cells into the clinic [25]. 
In 2008, Lu et al. reported differentiation of human ES cells into functional oxygen-
carrying erythrocytes on a large scale with up to 60% enucleation rate [26]. In 
comparison, differentiation of iPSCs along the erythroid lineage generated ortho-
chromatic (nucleated) erythroblasts and reticulocytes. In most reports, the differ-
entiated red blood cells express mainly fetal and embryonic globins, but very little 
adult-type (β-) globin [27]. This is likely due to the low level of erythroid Kruppel-
like factor 1 (EKLF1) and absence of BCL11A in these iPSC-derived red blood cells. 
These two factors have been demonstrated to be essential for the developmental 
switch from fetal to adult globin expression [28]. Inducible expression of KLF1 
during later stages of the differentiation process has been recently demonstrated to 
enhance differentiation and maturation of red blood cells from both human ES cells 
and iPSCs [29].
Recent advances in the development of programmable site-specific nucle-
ases, including zinc-finger nuclease (ZFN), transcription activator-like effector 
nucleases (TALENs), and the clustered regularly interspaced short palindromic 
repeat (CRISPR)-associated protein (Cas)9 system, have enabled target-specific 
introduction of transgene or correction of disease-specific mutations by homolo-
gous recombination, creating novel opportunities not only for disease modeling 
and drug testing but also generation of genetically corrected cells for autologous 
transplantation (Figure 2).
The development of iPSC technology has also revolutionized the future treat-
ment for end-stage organ failure. Takebe et al. recently reported vascularized 
and functional mini-livers or liver buds created in vitro based on human iPSCs 
[30]. In this proof-of-concept demonstration, the authors first prepared hepatic 
endoderm cells from human iPSCs by directed differentiation. About 80% of 
the differentiated cells express liver-specific marker HNF4A. To recapitulate 
early organogenesis, the investigators next cultured the iPSC-derived hepatic 
endoderm cells with two stromal cell populations, i.e., human umbilical vein 
endothelial cells and human mesenchymal stem cells (MSCs), in a traditional 
two-dimensional culture condition. Intriguingly, the iPSC-derived hepatic cells 
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self-organized into three-dimensional cell clusters that resemble in vivo liver buds 
during embryonic development. Moreover, within 48 hours of transplantation 
into the nonobese diabetic/severe combined immunodeficiency disease (NOD/
SCID) mice, the vasculatures in the iPSC-derived liver buds became functional by 
connecting to the host vessels, which further stimulated the maturation of iPSC-
derived liver buds into the tissue resembling the adult liver. Considering critical 
shortage of donor organs, development of iPSC-derived organoids suggests an 
alternative and innovative regenerative approach for patients with end-stage 
organ failure.
New advances have also been made in cardiac tissue engineering for cardiovas-
cular diseases. The protocols for differentiating ES cells or iPSCs into cardiomyo-
cytes, smooth muscle cells, and endothelial cells that are the main functional cell 
types in the heart have been reported [31, 32]. However, although readily obtain-
able, the morphology, calcium handling, electric coupling, contraction stress, and 
electrophysiology of the PSC-derived cardiomyocytes have been demonstrated 
to be immature compared to adult cardiomyocytes (reviewed in [33]). With that, 
significant bioengineering efforts have been made to recapitulate environmental 
cues to enable maturation of newly differentiated cardiomyocytes and to promote 
vascular network formation (reviewed in [34]). To address the need for tissue and/
or organ transplantation, there are also exciting advances in incorporating biocom-
patible materials, cells, and supporting components into complex 3D functional 
living tissues [35]. Excitingly, Noor et al. recently reported a 3D printing of thick, 
vascularized, and perfusable cardiac patches that fully match the immunologi-
cal, biochemical, and anatomical properties of the patient [36]. This was the first 
report on the use of fully personalized, non-supplemented materials as bioink for 
3D printing. In this study, fatty tissue was extracted from a patient. The cells from 
the tissue were reprogrammed to iPSCs, followed by directed differentiation into 
cardiomyocytes and endothelial cells. The remaining fatty tissue was decellularized 
and processed to generate a thermo-responsive hydrogel. The iPSC-derived cells 
Figure 2. 
Development of iPSC gene correction and autologous transplantation therapy. Biopsies such as the skin or 
blood can be obtained from a patient with genetic mutations and reprogrammed into patient-specific iPSCs. 
Through targeted nuclease technologies, such as zinc-finger nuclease which contains sequence-specific DNA-
binding domain fused to a non-specific Fok1 endonuclease enzyme, transcription activator-like effector 
proteins consisted of tandem DNA-binding repeats linked with the Fok1 enzyme, and the most recent method 
of CRISPR/Cas system that utilizes a single-guide RNA (sgRNA) and a protospacer adjacent motif for efficient 
genome targeting and binding followed by activity of the Cas enzyme, a double-stranded break (DSB) occurs at 
the target site of genome, inducing activation of internal DNA repair mechanism. Homologous recombination 
(HR) can then be achieved to incorporate exogenously transduced donor DNA to repair the mutations in the 
genome. After validation of the target-specific gene correction, the corrected iPSCs can be further differentiated 
into a cell type of preference for autologous transplantation.
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were then encapsulated with the hydrogel and served as the bioink for 3D printing 
of vascularized patches and complex cellularized structures. The investigators of 
this study also pointed out the obstacles that need to be overcome for a more appli-
cable 3D printing, including efficient generation of a sufficient number of cells for 
the organ printing, identifying biochemical and physical cues for cell maturation 
and conditions for long-term cultivation and a higher-resolution imaging of the 
entire blood vessels for the blueprint of 3D printing, etc. Nevertheless, the results 
from these studies have shed light on developing autologous engineered tissue or 
organs for transplantation.
2.5 Xenogeneic generation of human organs using PSCs
With the growing knowledge of organogenesis and the aid of gene editing 
technologies, scientists are also pushing the boundary and creating interspecies 
chimeras to grow human organs in animals, which ideally could subsequently be 
transplanted into people. In 2017, Yamaguchi et al. demonstrated that injection 
of mouse PSCs in the blastocysts of apancreatic Pdx1mu/mu rats (TALEN-mediated 
disruption in Pdx1 gene, a master regulator for pancreas development) which 
resulted in generation of a mouse pancreas in the rat [37]. Moreover, when the 
mouse pancreas grown in the rat was transplanted into diabetic mice, they were able 
to cure diabetes in the recipients without the administration of immunosuppression 
[37]. Wu et al. subsequently reported the creation of the first human-pig chimeras 
by injecting human PSCs into pig blastocysts [38]. The success rate of generating 
human-pig chimeras was indeed very low, and the chimeras only carried very few 
human cells, less than one human cell per 100,000 pig cells. To date, no one has 
reported using gene editing techniques performed in rat embryos to disable the pigs 
forming a particular organ and enable the human cells to develop more humanlike 
organs. Ross et al. demonstrated the generation of sheep-human hybrids, and as 
a step further than the reported human-pig chimeras, the contribution of human 
cells in sheep embryos was increased to one in 10,000 sheep cells [39]. Although 
these studies represent only a preliminary step toward the long-term goal, the 
results from these studies suggest that such creation may be eventually used to 
grow human organs. As the pigs and sheep are similar in size to humans, the human 
organs grown in these animals, the heart, liver, kidney, pancreas, lungs, and brain, 
could be harvested and transplanted into people, meeting the high demand for 
organ transplantation in the end-stage diseases. In addition, these human-animal 
chimeras could also be used to investigate the mechanisms of prenatal development 
and to investigate experimental drugs in different diseases.
Despite all the promises of using human/nonhuman chimeras for regenerative 
medicine, they also have raised serious ethical dilemmas about the morality of these 
chimeras. One of the biggest concerns is whether the human cells migrate to the 
brain and the chimeras end up with a humanlike mind. Such issues could potentially 
be prevented through genetic editing to avoid the human cell differentiating into 
the human brain or human gonads. So far, investigations in this field are moving 
forward with caution, and the reported human/nonhuman chimeras have not been 
allowed to develop past the fetal stage.
2.6 iPSC banking and allogeneic cell therapies
Although the iPSC cell therapy theoretically enables autologous transplanta-
tion, which would eliminate the need for immunosuppression, the inefficiency of 
iPSC derivation, the time and cost for developing each personalized cell product, 
and the safety of the products have made such autologous therapies unpractical, 
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particularly for diseases that require an immediate treatment. For the clinical 
use of iPSC-based cell therapies, it is essential to produce high-quality and safe 
(no induced mutations in the genome) iPSCs. As will be mentioned below, the 
pioneering iPSC clinical study in Japan using patients’ own iPSC-derived retinal 
epithelial cells for the treatment of macular degeneration was put on hold due 
to genomic mutations in the iPSCs. Therefore, the most feasible application of 
iPSC-based cell therapy would rely on the banked and human leukocyte anti-
gen (HLA)-typed iPSCs, in which the quality and safety have been validated in 
advance, in the setting of an allogeneic transplantation. This use of allogenic iPSCs 
however means that immunosuppression would have to be applied to prevent 
immune rejection. Kawamura et al. recently demonstrated that even though the 
immunogenicity of allogenic iPSC-derived cardiomyocytes was reduced by major 
histocompatibility complex (MHC) class I- and class II-matched transplantation 
in the macaque (monkey), the recipients still required substantial and highly 
toxic immunosuppression for sustained allogeneic cell engraftment [40]. It has 
been suggested that the MHC-matched iPSC-derived cardiomyocytes were still 
susceptible to natural killer (NK) cell destruction, leading to their rejection in 
the recipients in the absence of immunosuppression [40]. Forced expression of 
HLA alpha chain E (HLA-E) in PSCs and their differentiated derivatives has been 
demonstrated to prevent allogeneic response and lysis by NK cells [41]. Recently, 
Deuse et al. looked into the expression of genes in syncytiotrophoblast, an inter-
face between fetus and mother, and identified low MHC class I and II expression 
and a high CD47 expression as the features that are responsible for the immune 
tolerance of syncytiotrophoblast toward allogenic fetal antigens [42]. CD47 is 
a membrane protein that interacts with several cell surface receptors to inhibit 
phagocytosis [43]. Indeed, CD47 is a “don’t eat me” signal highly expressed on the 
surface of cancer cells to escape the innate immune responses [44]. The authors 
then inactivated MHC class I and II genes through CRISPR-Cas9 targeting and 
overexpressed CD47 via lentiviral transduction in both human and mouse iPSCs 
[43]. Importantly, the engineered iPSCs and derivatives (endothelial cells, smooth 
muscle cells, and cardiomyocytes) lost their immunogenicity and persisted long 
term in fully MHC-mismatched recipients without the use of immunosuppres-
sion [43]. This suggests that hypoimmunogenic cell grafts can be engineered 
from iPSCs for universal transplantation without immunosuppression. These 
approaches are associated with potential risks of uncontrollable malignant trans-
formation or impaired immune reactions using hypoimmunogenic cell grafts, and 
consideration of designing an inducible killing switch in the engineered cells to 
ensure overall safety should be taken into account.
2.7 Current clinical trials with iPSCs
In 2014, Mandai et al. reported the results of the world’s first clinical study of iPSC-
based therapy in patients with advanced neovascular age-related macular degenera-
tion (AMD) [45]. In this trial, two patients were recruited, and iPSCs were generated 
from the skin fibroblasts and were further differentiated into retinal pigment 
epithelial (RPE) cells [45]. One patient received the autologous iPSC-derived RPE 
cell sheet under the retina. A one-year follow-up on this patient revealed no apparent 
improvement nor worsening in her vision, and the transplanted sheet remained intact 
[45]. For the other patient, however, aberrations in DNA copy number were identi-
fied in the derived iPSCs and RPE cells, but not the starting fibroblasts, implying that 
genome mutations occurred during the reprogramming process [45]. This patient 
did not receive the treatment. Indeed, this clinical trial was suspended due to the 
9Innovations in Human Stem Cell Research: A Holy Grail for Regenerative Medicine
DOI: http://dx.doi.org/10.5772/intechopen.88790
discovery of genetic mutations in the iPSCs. In 2017, five patients were recruited and 
treated for the same eye condition with iPSC-derived retinal cells. However, in this 
trial, the iPSCs were of an allogeneic source and created at Kyoto University Center 
for iPS Cell Research and Application (CiRA). One of the patients developed a serious 
reaction to the transplant. After removal of the engineered membrane graft, the 
symptoms were improved [46]. The efficacy of the treatment in other patients has not 
been reported.
In addition to the iPSC-based therapies in AMD, in May 2018, Japan’s health 
ministry approved cardiac surgeon Yoshiki Sawa at Osaka University to assess the 
safety of allogeneic iPSC-derived cardiomyocytes in patients with heart disease 
[47]. This research team has previously reported the efficacy of grafting of human 
iPSC-derived cardiomyocytes cell sheet in combination with an omental flap 
technique in a porcine model of ischemic cardiomyopathy [48, 49]. In the projected 
human trial, the treatment will initially be given to three people; then the team will 
seek approval to conduct a clinical trial in approximately 10 patients [47]. If these 
initial clinical studies prove successful, the treatment will be made commercially 
available soon after under a new fast-track system in Japan designed to speed up the 
development of regenerative therapies [47].
In October 2018, neurosurgeons at Kyoto University Hospital also performed the 
first iPSC cell-based therapy in patients with Parkinson’s disease (https://www.kyoto-
u.ac.jp/en/research/events_news/department/hospital/news/2018/181109_1.html). In 
this first human study, 2.4 million allogeneic iPSC-derived dopamine precursor cells 
were deposited into 12 sites of the patient’s brain with known dopamine activity. At the 
time of the press conference on this procedure, November of 2018, the investigators 
described that the patient was “doing well.” The human iPSC-derived progenitor cells 
have shown to improve the symptoms in a primate model of Parkinson’s disease [50].
As compared to Japan’s fast-forwarding pace of initiating human trials with 
iPSC-based therapies, the scientists and physicians in the United States are 
approaching this direction with more caution, even though several human ES 
cell-based therapies have been initiated in clinical studies [51]. For the treatment of 
Parkinson’s disease, Lorenz Studer at Memorial Sloan Kettering Cancer Center has 
focused on generating dopamine neurons from human ES cells at a sufficient scale 
and purity and demonstrated their efficient engraftment and function in mouse, 
rat, and monkey models of Parkinson’s disease [52]. Based on those results, the 
group is currently pursuing an investigational new drug (IND) application from the 
US Food and Drug Administration (FDA), to initiate the first human clinical use 
of ES cell-derived dopamine neurons [52]. In November 2018, Fate Therapeutics, 
Inc., a biopharmaceutical company, announced that the FDA approved their IND 
application for FT500, the company’s universal NK cells derived from a clonal 
master iPSC line. Using an in vitro three-dimensional tumor spheroid model, the 
company demonstrated that FT500, in combination with activated T cells and 
an anti-programmed death (PD)-1 antibody, led to near-complete elimination of 
target cells (>99% reduction) [53]. The company plans to initiate first-in-human 
clinical testing of FT500 in combination with checkpoint inhibitor therapy for the 
treatment of advanced solid tumors. This is expected to be the first-ever clinical 
investigation in the United States of an iPSC-derived cell product.
In 2016, Cynata Therapeutics also launched a phase I clinical trial in both the 
United Kingdom (UK) and Australia using allogeneic iPSC-derived MSCs (differenti-
ated from iPSCs through intermediate-stage mesenchymoangioblasts) (CYP-001) for 
the treatment of steroid-resistant acute graft-versus-host disease (aGvHD) in patients 
undergoing an allogenic stem cell transplantation. In 2018, the company reported that 
CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy 
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data for the treatment of steroid-resistant aGvHD in a phase 1 trial. Cynata plans to 
advance the cell product into phase 2 trials for GvHD and critical limb ischemia.
3. Adult (somatic) stem cells
3.1 Tissue-resident adult stem cells
Tissues and organs in our body constantly regenerate throughout our lives. 
Human red blood cells have a defined life span of 120 days [54]. The lining in the 
intestine turns over completely about every 7 days [55]. Skin cells are constantly shed 
and then renewed. Endothelial cells in the human heart have a > 15% turnover rate 
per year, while cardiomyocyte exchange is highest in early childhood and decreases 
gradually throughout life to <1% per year in adulthood [56]. These are examples 
of cell turnover at a steady state. Some organs, such as the liver, display relatively 
slow tissue turnover at a steady state, however upon damage, undergo bursts of cell 
proliferation and repair [57]. Essential for such replenishment and repair in post-
natal life are the activities of adult stem cells. Adult stem cells are undifferentiated 
tissue-resident cells capable of self-renewal and differentiation within the tissue 
or organ. Self-renewal allows replication of themselves to sustain their population, 
and differentiation enables replenishment of various mature cell types upon tissue 
remodeling and repair, to maintain tissue homeostasis throughout postnatal life.
Hematopoietic stem cells (HSCs) are the first identified adult stem cells [58, 59]. 
The idea of HSCs, however, can be traced back before the experimental proof of 
HSCs and following the atomic bombing of Hiroshima and Nagasaki, when the civil-
ians exposed to irradiation were documented to have symptoms of hematopoietic 
failure. Subsequent experiments in mice demonstrated recovery of the hematopoietic 
system after radiation injury by bone marrow transplantation [60]. These studies 
and subsequent transplantation experiments in mice with acute leukemia [61] led 
to pioneering of allogeneic hematopoietic stem cell transplantation (alloHSCT) by 
Thomas et al. in patients treated with radiation and chemotherapy in 1957 [62]. At 
that time, little was known about HLAs, and there was no matching between donors 
and recipients, until the mid-late 1960, when methods to identify HLA were devel-
oped [63]. While many physicians had doubts on the approach of alloHSCT, Thomas 
et al. persevered and performed transplantation using a matched sibling donor for 
a patient with leukemia in 1969 [64, 65]. Eight years later, his team performed the 
first HLA-matched transplant from an unrelated donor, a success that led to the 
formation of a national registry of bone marrow donors [63]. Dr. Thomas received 
the 1990 Nobel Prize in Physiology or Medicine with Dr. Joseph Murray, who per-
formed the first successful kidney transplant, for their contribution to cell and organ 
transplantation.
For decades, hematopoiesis has been described as a cellular hierarchy where only 
one type of HSC is sitting at the apex of the hierarchy and giving rise to lineage-
restricted progenitors, which further differentiate into all the cell types of the blood 
[66]. However, accumulating data on single HSC repopulation and serial transplan-
tation have revealed an inherent heterogeneity in self-renewal and multi-lineage 
differentiation of HSCs [67, 68]. These and other studies have contributed to a 
change of view on HSCs from a single stem cell-type hierarchy model to a consor-
tium model where a pool of stem cells with slightly different properties regenerate 
all the blood types [69–71]. However, a recent study suggested that platelet-biased 
stem cells, primed toward the megakaryocyte lineage, reside at the apex of the HSC 
hierarchy [72]. To reconcile with different observations on HSCs, a new speculative 
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model was further raised suggesting that stem cells are rare reserve cells that 
occasionally generate lineage-restricted progenitors [73]. Some progenitors may 
retain a degree of developmental flexibility and, during extreme stress, can revert to 
a stemlike state [73].
Adult stem cells have been identified in most, if not all, tissues and organs in 
our body, as well as the placenta and cord blood (CB) (Figure 3). Extensive studies 
have been performed to characterize the adult stem cells in the fast-regenerating 
organs such as the skin and intestine [74, 75]. Moreover, the organs that were once 
thought to be non-regenerative, such as the brain and heart, also contain adult stem 
cells, i.e., neural stem cells and cardiac stem cells, respectively [76, 77]. In addition, 
similar to the evolving concept of hematopoiesis [73], heterogeneity of stem cell 
populations in distinct compartments in these organs has also been demonstrated, 
and the heterogeneity enables them to adapt to diverse roles and functions in 
response to environmental stimulation [73].
3.2 Adult stem cell niche and aging
It has been well accepted that the activities of adult stem cells, whether they stay 
quiescent or undergo activation, are largely instructed by the microenvironment 
they reside in, i.e., stem cell niche. Extensive studies have been performed to char-
acterize the stem cell niche in different organ systems such as the skeletal muscle, 
bone marrow, skin, intestines, and brain (reviewed in [78]). There are common 
features of the adult stem cell niche. In general, the stem cell niche or microenvi-
ronment is composed of stem cells themselves and progeny, surrounding MSCs or 
stromal cells, extracellular matrix, and adhesion molecules, as well as the external 
cues from distant sources (long-range signaling factors) [78]. Collectively, both 
cellular and acellular components of the stem cell niche create a complex microen-
vironment maintaining stem cell fate and ensuring robust regenerative responses 
to external stimuli. Although other signaling pathways have been described, TGFβ 
Figure 3. 
Identification of adult stem cells from postnatal organs and tissues such as the brain, eye, teeth, lung, heart, 
kidney, intestine, skeletal muscle, fat tissue, bone marrow, skin, and reproductive system. Human placenta and 
cord blood are also rich in different hematopoietic stem cells and progenitors, as well as non-hematopoietic 
stem cells.
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superfamily, Wnt pathway, and Notch signaling have been identified in different 
model systems as key regulators of stem cell quiescence, survival, maintenance, 
and activation [78]. For example, the TGFβ superfamily not only contributes 
to stem cell quiescence maintenance [79–81], it also plays an important role for 
stem cell activation and aging. TGFβ has been found to be upregulated in both the 
satellite cells (skeletal muscle stem cells) and serum of aged mice, which induces 
high levels of pSmad3 in satellite cells and interferes with their regenerative activi-
ties [82]. Importantly, Notch signaling antagonizes pSmad3 and controls satellite 
cell proliferation by blocking TGFβ-dependent upregulation of cyclin-dependent 
kinase inhibitors [82]. Meanwhile, increased Wnt signaling in the aged satellite cells 
has been demonstrated to contribute to cell fate conversion of satellite cells from a 
myogenic to a fibrogenic state [83].
Recently, Tikhonova et al. mapped the transcriptional landscape of mouse bone 
marrow microenvironment (HSC niche) at a single-cell resolution and reported 
previously unappreciated levels of cellular heterogeneity within the niche and with 
defined distribution of pro-hematopoietic factors [84]. Furthermore, bone marrow 
niche underwent transcriptional remodeling under stress conditions, leading to a 
significant upregulation of adipogenesis-related pathways and a global reduction 
in osteo-lineage-related gene expression [84]. There was also a downregulation of 
vascular-endothelial-expressed Notch ligand DLL4, which skewed bone marrow 
hematopoiesis toward a myeloid transcriptional program [84]. These results indeed 
provided an explanation to the observation that the HSC populations in the elderly 
exhibit myeloid skewing and lymphoid lineage deficiency [85].
The notion of aging has been raised as the ratio of tissue attrition to tissue 
regeneration [86]. This process is accompanied by reduced regenerative capacity 
of adult stem cells at levels of both self-renewal and differentiation (reviewed in 
[87]). The decline in regenerative function of adult stem cells also contributes to 
pathophysiological alterations in age-related diseases. Meanwhile, current stud-
ies also indicate that age-imposed biochemical changes in the stem cell niche are 
responsible for such regenerative declines of tissue maintenance and repair. Indeed, 
several studies have revealed that regenerative potential of stem cells was not 
controlled by the age of the stem cells themselves, but by the age of the niche they 
stay in [86]. In a classic experiment, minced skeletal muscle tissue containing satel-
lite cells from young rodents was transplanted into the muscle of aged hosts, and 
conversely muscle tissue from old rodents was placed into the muscle of young hosts 
[88]. Such heterochronic transplantation demonstrated that the age of the host was 
more important than the age of the transplanted stem cells in muscle regeneration 
[88]. Serial transplantation of spermatogonial stem cells to the testes of young male 
mice demonstrated that spermatogenesis from that stem cell could continue for 
more than 3 years, long past the normal life span of the animal, when the stem cell 
is continually maintained in a young niche [89]. The importance of stem cell niche 
is further revealed by the heterochronic parabiotic studies [83, 90, 91]. In such 
experiments, two rodents, young-to-old (heterochronic) and young-to-young and 
old-to-old (isochronic), are surgically connected through a large flap of the skin, 
allowing vascular circulation between the two connected animals. In these studies, 
the isochronic parabionts were not significantly different in tissue regeneration than 
their respective non-parabiotic age-matched controls. However, in the heteroch-
ronic parabionts, regeneration in the muscle, liver, and brain was all significantly 
improved for the old animal and was decreased for the young animal [83, 90, 
91]. As there was no evidence of blood cell exchange between the two connected 
animals, the studies suggested that tissue regeneration in the stem cells of an old 
animal could be promoted by “young” systemic factors (long-range factors), while 
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the aged circulation might have “negative” regulators that suppress the regenera-
tive activities of “young” adult stem cells [86]. Examples of identified “negative” 
factors include p16INK4a, C-C motif chemokine 11 (CCL11), TGFβ, and TNFα, and 
“young” factors are sirtuin 6 (SIRT6) and Delta/Notch [82, 91–94].
All these studies underscore the importance of understanding how the stem 
cell microenvironment controls stem cell dynamics and function. Identifying 
specific molecular and cellular mechanisms that either rejuvenate or compromise 
the regenerative capacity of adult stem cells will be instructive in developing 
therapies antagonizing aging and age-related pathological changes. In animal 
studies, it has been demonstrated that forced activation of Notch signaling and 
inhibition of TGFβ and Wnt pathways could restore the regenerative capacities of 
aged muscle [83, 95].
Understanding the impact of microenvironment on stem cell activities is 
also essential for the development of an effective stem cell therapy. Whether the 
cells are derived from pluripotent stem cells or isolated from adult tissue, ex vivo 
culture or manipulation in a microenvironment that maintains cell identity and 
potency is critical for the efficacy of cell transplantation. Furthermore, a substan-
tial challenge in the regenerative therapy is acute cell death after transplantation 
of the cells into a degenerative/pathological microenvironment. A recent clinical 
islet transplantation study quantitated the level of circulating cell-free (cf) DNA 
as a biomarker for the dead beta cells after transplantation [96]. The authors 
reported that a distinctive peak of cfDNA was observed 1 hour after transplanta-
tion in 83.8% of patients. The cfDNA was also detected 24 hours posttransplant, 
and that signal was correlated with overall poor clinical outcome (higher insulin 
requirement, lower stimulated C-peptide level, and decreased 3-month engraft-
ment) [96]. Instant blood-mediated inflammatory response has been speculated 
to contribute to the significant graft attrition at this early stage of transplant [97]. 
Therefore, modulation on microenvironment that ensures the survival, integra-
tion, and function of the therapeutic cells after transplantation would greatly 
improve the efficacy of cell therapies.
3.3 Mesenchymal stem cells
MSCs were initially identified as rare non-hematopoietic colony-forming units 
following plastic adherence of bone marrow cells (reviewed in [98]). Although the 
original notion of MSCs specifically referred to cells in the bone marrow (also called 
bone marrow stromal cells, BMSCs), MSCs have been derived from other sources 
such as cord blood, adipose tissue, and dental pulp. MSCs can be identified by the 
expression of cell surface markers including CD90, CD73, and CD105 and lack of 
expression of hematopoietic and endothelial cell markers. MSCs have the capacity 
to differentiate along mesoderm lineage into osteoblasts, chondrocytes, adipocytes, 
and fibroblasts. MSCs were also reported to give rise to other mesodermal cell types 
such as cardiomyocytes and endothelial cells, as well as the cells of other lineages 
such as neurons and hepatocytes. However, as these claims were mainly based on 
the expression of the markers and not functional studies, whether MSCs truly have 
such differentiation capacities require more extensive validation.
There are also controversial results on the age-related changes in MSCs. Some 
studies reported an age-dependent reduction in the number of MSCs isolated from 
human bone marrow, while others demonstrated no correlation between MSC 
numbers and age, even in patients with osteoarthritis [99–102]. Functionally, Sun 
et al. demonstrated using young and aged mice that although the frequency of 
MSCs was not significantly different between the young and old bone marrow, the 
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self-renewal and bone formation capacity of old MSCs were significantly com-
promised as compared to the young MSCs [103]. Moreover, similar to the finding 
in the satellite cells, exposure of the aged MSCs to a young extracellular matrix 
rejuvenated these functions of aged MSCs [103]. Recent studies also demonstrated 
that with age as well as treatment of antidiabetic drugs, MSCs favored differentia-
tion into adipocytes resulting in an increased number of adipocytes and a decreased 
number of osteoblasts, which may be related to osteoporosis. Downregulation of 
a transcription factor c-Maf has been identified as the age-related switch in MSC 
differentiation [104].
3.4 Human umbilical cord blood and placental stem cells
The idea to use human umbilical cord blood arose in the early 1980s, when 
experiments using cord blood from near-term mice demonstrated hematopoietic 
reconstitution in lethally irradiated mice [105]. Further, cord blood-derived HSCs 
were found to have a higher proliferative capacity than those in bone marrow and 
sufficient doses of HSCs, and hematopoietic progenitor cells were contained in a 
single collection of cord blood [106]. In 1988 a 5-year-old boy with Fanconi anemia 
underwent the first cord blood transplantation from his HLA-identical newborn 
sister [107]. In 1993 the first unrelated cord blood transplantation was performed in 
a 3-year-old with refractory T-cell acute lymphoblastic leukemia. Since then, related 
and unrelated cord blood has been increasingly utilized as an alternative source of 
HSCs [108].
In addition to the HSCs and hematopoietic progenitors, many populations of 
non-hematopoietic stem cells have been reported in human cord blood, such as 
MSCs, endothelial progenitor cells [109], embryonic-like stem cells (CBE) [110], 
very small embryonic-like (VSEL) stem cells [111], multi-lineage progenitor cells 
(MLPC) [112], and unrestricted somatic stem cells (USSCs) (Figure 3) [113]. 
There have been controversial reports on the identity of VSEL. VSEL stem cells 
were isolated based on the sorting of CXCR4+SSEA-1+Sca-1+Lineage−CD45− cells 
originally from murine bone marrow cells and subsequently in human CB [111]. 
Several other groups also reported the isolation of VSEL cells from different adult 
tissues and implied that VSEL cells were originated during embryonic development 
and deposited in bone marrow and other organs as dormant precursor cells of adult 
stem cells (reviewed in [114]). These cells are reported to be very small (3–5 μm), 
possess large nuclei, express pluripotency markers Oct4 and Nanog, and undergo 
multi-lineage differentiation. However, the stem cell characteristics of this cell type 
were challenged by the other group [115].
Among the other cord blood-derived non-hematopoietic stem cells, USSCs are 
the best characterized stem cell population and represent a novel universal allogenic 
stem cell source for degenerative diseases. USSCs are generated from full-term CB 
based on outgrowth of plastic adherent and spindle-shaped colonies in the presence 
of 30% fetal bovine serum, 10−7 M dexamethasone, and 2 mM ultra-glutamine in 
low glucose DMEM [113]. USSCs possess the ability to differentiate in vitro into the 
bone, cartilage, adipocytes, hematopoietic cells, and neural cells and in vivo into 
myocardial cells, Purkinje fibers, and hepatic cells [113]. Although USSCs share cell 
surface marker with MSCs, they have distinct gene expression, epigenetic signatures, 
and cytokine profiling [113, 116–120]. USSCs have high proliferation and expansion 
properties. They can be cultured for more than 20 passages without any spontaneous 
differentiation or slowing down doubling time [113, 116]. This is a significant advan-
tage of USSCs over MSCs, the doubling time of which dramatically increases after 
four passages, leading to cell senescence [121]. Significantly, even after 13 passages, 
the average telomere length of USSCs is 8.6kbp, which is significantly longer than 
15
Innovations in Human Stem Cell Research: A Holy Grail for Regenerative Medicine
DOI: http://dx.doi.org/10.5772/intechopen.88790
the 7.27kbp telomere length of MSCs at passage 4 [113]. In preclinical studies, USSCs 
demonstrated the ability to alleviate myocardial infarction, liver injury, spinal cord 
injury, and intraventricular hemorrhage [122–124]. Moreover, USSCs also promote 
wound healing and improve manifestation of an inherited skin blistering disease, 
i.e., RDEB [120, 125]. Suppression of TGFβ-mediated fibrosis and modulation of 
extracellular matrix remodeling have been accounted as part of the mechanisms of 
action of USSCs in the treatment of RDEB (Figure 4) [125].
Once considered as a medical waste similar to CB, the human placenta has 
also been demonstrated to provide a novel stem cell source for cellular therapy. 
Hematopoietic stem and progenitor cells were identified throughout gestation 
from human placental blood, vessel perfusate, and cells from digested placenta 
tissue, and stromal cells generated from placenta possessed pericyte characteristic 
and may be a supportive microenvironment for hematopoiesis [126]. Recently 
Celgene Cellular Therapeutics, Inc. manufactured human placental-derived stem 
cells (HPDSCs) from full-term donor placentas following saline perfusion, red 
blood cell depletion, and volume reduction. The overall cell types as determined 
by flow cytometry analysis are similar between HPDSCs and CB [127]. However, 
HPDSCs contain a significantly higher level of both hematopoietic and non-hema-
topoietic stem and progenitor cells than CB. In addition, HPDSCs have a lower 
percentage of T cells than CB and are largely negative for MHC class II molecules, 
indicative of their potential use as both autologous and allogeneic cells. A pilot 
clinical study demonstrated that adding HPDSCs as universal donor cells with 
CB transplantation in patients with malignant and nonmalignant diseases had no 
adverse effects and may reduce the incidence of aGvHD [128]. Administration of 
HPDSCs in a mouse model of RDEB, in the absence of any conditioning regimen, 
also resulted in significant improvement on the survival and disease manifestation 
of the recipient mice [127].
Figure 4. 
Dual effects of cord blood-derived USSCs on modulating RDEB skin microenvironment. USSCs exert anti-
fibrotic function by suppressing phosphorylation of Smad2/3 in the fibroblasts (Fb) and macrophages (MΦ) 
of the skin, inhibiting matrix metalloproteinases (MMP)-9 and -13 dermal expression and upregulating anti-
fibrotic TGFβ3 and DCN expression. USSCs also attenuate secretion of MMP-9 and MMP-13, which correlate 
with epithelial malignant transformation, from keratinocytes (Kc) and cutaneous squamous cell carcinoma 
(cSCCs) derived from patients with RDEB. This figure was adapted from Stem Cells with permission [125].
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As will be mentioned below, CB hematopoietic progenitor cells are among the 
few stem cell products that are approved by the FDA. Over 40,000 CB transplanta-
tions have been performed worldwide in both adults and children for the treatment 
of around 80 different disorders [129]. The advantage of using CB and cord blood 
CB-derived stem cells compared to other adult stem cell sources is the fast avail-
ability and ease in collection without causing any discomfort or risk to the donors. 
Moreover, being early in development, CB stem cells have not been exposed to 
immunological challenge and are less likely to carry somatic mutations than other 
adult cells. Any age- or stress-related transcriptional remodeling that might have 
impacted the stem cell function of adult stem cells, as discussed above, would not 
be of an issue in CB stem cells.
3.5 Examples of clinical studies with adult stem cells
As of today, FDA-approved cellular and gene therapy products are limited to 
the hematopoietic progenitor cells from CB for alloHSCT in patients with disorders 
affecting the hematopoietic systems, autologous chondrocytes on a porcine col-
lagen membrane for repair of cartilage defects of the knee, allogeneic cultured 
keratinocytes and fibroblasts in the treatment of mucogingival conditions, and 
a few chimeric antigen receptor (CAR) autologous cellular immunotherapies 
(https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/
approved-cellular-and-gene-therapy-products).
In addition to the treatment of the disorders affecting hematopoietic system, 
CB alloHSCT has also been applied in clinical trials to treat nonmalignant diseases. 
More than 20 years ago, CB transplantation had been initiated in infants and 
children with Krabbe’s disease [130, 131]. Krabbe’s disease is an autosomal reces-
sive disorder due to deficiency of the lysosomal enzyme galactocerebrosidase, 
leading to progressive neurologic deterioration and death in early childhood. 
These transplantation studies demonstrated that CB cells, both hematopoietic and 
non-hematopoietic in origin, could engraft in the patients’ central nervous system, 
providing the missing enzyme and facilitating neural cell repair. Particularly, 
the young patients that underwent transplantation before the development of 
symptoms showed significant improvements in developmental skills, while the 
children who underwent transplantation after the onset of symptoms had minimal 
neurologic improvement [130, 131]. A long-term follow-up (median 9.5 years, 
range 4–15 years) study further demonstrated that the surviving patients 
who underwent early CB transplantation function at a much higher level than 
untreated children or children who were symptomatic at the time of alloHSCT 
[132]. Based on the observed efficacy of CB transplantation on improving neu-
rological outcome, Cotten et al. conducted a pilot study on intravenous infusion 
of autologous CB in 184 pediatric patients who had their CB banked at birth and 
were subsequently diagnosed with acquired neurological disorders [133]. This 
investigation demonstrated the safety and feasibility of autologous CB infusion in 
these pediatric recipients. Subsequently, Cotten et al. also reported the safety and 
feasibility of autologous CB infusion in neonates diagnosed as hypoxic ischemic 
encephalopathy [134].
Over the last two decades, there have been an increasing number of clini-
cal trials involving stem cell treatment for various degenerative diseases. For 
cardiovascular disease alone, there have been more than 200 clinical trials using 
various cell types including skeletal myoblasts, autologous bone marrow mono-
nuclear cells (BMMNCs), CD133+ bone marrow cells, endothelial progenitors, 
autologous CD34+ cells, MSCs, cardiopoietic stem cells that were generated by 
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treating MSCs with a cocktail of trophic factors, allogeneic and autologous c-kit+ 
cardiac stem cells isolated from biopsies obtained during coronary artery bypass 
grafting, and cardiosphere-derived cells generated from culture outgrowth of 
heart biopsies (reviewed in [135]). Most studies demonstrated that the tested 
cells were safe and the procedures were feasible. However, the efficacy of these 
cell therapies remains inconclusive. Early clinical trials, ranging from pilot 
to phase III double-blinded placebo-controlled studies, such as TOPCARE-
AMI, BOOST, FNCELL, and REPAIR-AMI, demonstrated significant efficacy 
(evaluated-based on left ventricular ejection fraction, LVEF) of BMMNC treat-
ment in patients with acute myocardial infarction. However, recent multicenter, 
double-blinded, and placebo-controlled studies, such as TIME, LateTIME, and 
SWISS AMI trials, found no improvements after BMMNC administration in 
LVEF and other parameters measured by cMRI. Even the same center, which 
reported significant improvement in heart function in the initial pilot trial and 
subsequent partly randomized and open-label study on autologous CD133+ 
bone marrow cell infusion during coronary artery bypass graft surgery [136, 
137], later revealed no significant benefits of CD133+ bone marrow cell infu-
sion in a strictly double-blind, fully randomized, and placebo-controlled trial 
(CARDIO133, NCT00462774) [138]. It has also to be mentioned that a report on 
the initial results of a phase I, open-label, and randomized trial using autologous 
c-kit+ cardiac stem cells in patients with ischemic cardiomyopathy was recently 
retracted from the journal, due to lack of reliability on the production of cells 
and integrity of the data [139].
3.6 Lessons learned from clinical stem cell therapies
Although there are a substantial number of clinical studies, it is difficult to 
compare results between trials. Sources of cell products, mode of cell delivery and 
cell dose, timing of administration, the age and complications of patients, and the 
choice of surrogate endpoint markers are all the variables for the efficacy of each 
clinical study.
When it comes to a stem cell therapy, it is tempting to think of it as the cell 
replacement therapy, that is, the stem cells engraft and differentiate to replace the 
damaged cells in vivo. However, although a few studies demonstrated that MSCs 
could undergo tri-lineage differentiation and human CD34+ cells could fuse with 
cardiomyocytes and also transdifferentiate in animal models [140, 141], most 
studies reveal no evidence of therapeutic cells to undergo real cell replacement 
in vivo. Even c-kit+ cardiac stem cells and cardiosphere-derived cells do not become 
cardiomyocytes in experimental animals with infarction [142, 143]. Rather, para-
crine effects, e.g., secretion of growth factors to enhance tissue preservation and/
or recruitment of endogenous repair, have been considered as the major mode of 
action of stem cells 137,138. Similar lack of differentiation has also been reported 
when neural stem cells or progenitors were transplanted in animal models [144]. It 
would be interesting to see whether administration of human ES or iPSC-derived 
mature cells, such as cardiomyocytes and neurons as mentioned in the first part of 
the chapter, would result in more effective outcomes in the recruited patients, as in 
preclinical studies, these fully differentiated cells appeared to be able to function-
ally integrate in the recipient tissue [49, 50].
For cellular therapies, there is a choice of using either autologous or allogeneic 
cells. The autologous cells have the advantage of circumventing immunogenicity; 
however, the cell dose could be limited per isolation and the quality may not be 
reliable. Moreover, as mentioned above, the function of tissue stem cells declines 
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with age. It was also reported that BMMNCs isolated from patients with chronic 
ischemic heart disease have a significantly reduced migratory and colony-
forming activity in vitro and a reduced neovascularization capacity in vivo, as 
compared to healthy controls [145]. Therefore, for the patients that are elderly 
and suffer from pathological insults, they may not benefit from treatment using 
their own cells. For allogeneic cells, the cell dose is less of an issue than autolo-
gous cells. As off-the-shelf products, they are presumably validated for safety 
and efficacy before being applied to patients. However, generation of cell lots 
with consistent potency and comparability has been recognized as a significant 
issue for clinical translation. Recently, two independent investigations reported 
that clinical-grade human neural stem cell product (HuCNS-SC; proprietary of 
StemCells, Inc.), in contrast to the research-grade NSCs provided by the same 
company, failed to demonstrate the efficacy in animal models of spinal cord 
injury and Alzheimer’s disease, respectively [144, 146]. However, despite being 
informed of the negative impact of stem cell engraftment on functional outcome 
in the animal model, the company initiated a clinical trial testing this product in 
patients with cervical spinal cord injury (NCT02163876) in December 2014 and 
subsequently reported a small improvement in motor strength in 4/5 subjects 
in the 6-month interim report. However, the clinical trial was terminated in 
May 2016, due to a lack of significant improvements and the lack of a trend for 
improvements over time [146]. In this study, there were no details on how the 
clinical- and research-grade products were made differently that might contrib-
ute to the disparity on the efficacy of animal studies. HuCNS-SC was derived 
from donated fetal brain tissue based on fluorescence-activated cell sorting of 
CD133+ cells and expanded as neurospheres. It is possible that the clinical- and 
research-grade products were from different donors with varying genetic back-
ground and/or developmental stage. It is also possible that the scale-up produc-
tion of the cell products under good manufacturing practice (GMP) unfavorably 
changed the therapeutic function of the cells. Nevertheless, the lack of efficacy of 
the cell product in the animal model was consistent with the failure of the clinical 
trial. It has to be noted that in vivo preclinical testing of the final clinical product 
is not required by the FDA, because “human-derived cellular therapy products 
intended for clinical administration in animals may not be informative” [147]. As 
a result, stem cell products are increasingly entering clinical studies for various 
disease conditions without prior efficacy studies in animal models, outpacing 
our understanding on their potential mechanisms of action. Although it is true 
that not all the animal models recapitulate spectrum of human diseases and it is 
difficult to extrapolate the results from the animal study to human, the lesson 
learned from the failures of clinical studies including HuCNS-SC is the impor-
tance of robust and reliable potency assays to characterize the cells and to ensure 
the consistency between different manufacturing lots before applying to patients. 
Recently, the International Society of Stem Cell Research (ISSCR) released 
updated guidelines on stem cell research and clinical translation, recommending 
that the cells entering clinical trials are based on sound scientific rationales with 
robust manufacturing and animal efficacy data, in addition to a safety package to 
support clinical trials [148].
4. Conclusion
We are at the end of the beginning in the field of stem cell research and stem 
cell regenerative medicine. Particularly, the development of iPSCs and gene 
editing techniques have opened a new era of disease modeling and personalized 
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medicine. However, although it is feasible, the time and cost for production and 
validation of autologous iPSC-derived cellular therapeutics have made such 
personalized medicine unpractical, especially for diseases requiring an immedi-
ate therapeutic intervention. Therefore, a more feasible use of iPSCs and iPSC-
derived cell products would rely on an HLA-matched allogeneic setting. Moreover, 
targeted differentiation of PSCs into distinct cell subpopulations and proper cell 
maturation remain to be a challenge in the development of iPSC therapies. In the 
end, whether the cell products are derived from iPSCs or adult stem cells, they 
face the same challenges as cellular therapies, that is, large number of cell death 
after transplantation and poor functional integration of the survived cells. The 
current efforts on tissue engineering and organoid system have demonstrated 
promises in overcoming these difficulties. Understanding tissue microenviron-
ment is also the key to develop effective therapies that ensure exogenous cell 
engraftment and integration and/or augment endogenous tissue stem cell func-
tion for regeneration.
With the excitement of stem cell research, more subtypes of stem cells are 
entering into clinical studies, and there is a growing interest in commercializing 
and marketing of these stem cell products. However, caution should be maintained 
to ensure the quality of cell products and the scientific rationale and rigor for their 
clinical translation. Lastly, a randomized and controlled clinical trial with large 
sample size and multiple surrogate endpoints are essential to determine the safety 
and efficacy of stem cell therapy.
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